Skip to content

Serum/Plasma Line Blot for Liver Disease Markers (Immunoblot)

Published: August 9, 2026Updated: August 16, 2026

This test detects antibodies related to liver diseases, often used to identify conditions like autoimmune hepatitis or certain viral infections affecting the liver.

Quick summary

["Helps diagnose or monitor liver conditions by checking for specific immune responses."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
85092-5
Short code
Liver diseases IgG Pnl SerPl Line blot
Synonyms
Liver diseases IgG Pnl SerPl Line blot
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
line-blot
CPT
82784
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

What This Test Measures

The test uses a line blot assay to identify the presence of antibodies against various liver-specific antigens. This method can reveal markers linked to autoimmune processes, chronic infections, or metabolic liver diseases.

Why It’s Ordered

Your healthcare provider may recommend this test if you have symptoms like persistent fatigue, jaundice, abdominal pain, or if liver function tests (such as ALT, AST) are elevated. It’s also used in cases where other tests don’t clearly explain liver issues.

Sample Collection and Preparation

Blood is drawn from a vein, typically in your arm. The serum or plasma is then processed and analyzed in a lab to detect specific antibody lines on a blot.

Common Conditions Evaluated

This test can help identify antibodies associated with autoimmune liver diseases (e.g., autoimmune hepatitis), chronic viral hepatitis (e.g., hepatitis B or C), metabolic liver diseases (e.g., hemochromatosis), or other conditions causing chronic liver inflammation.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Positive results for certain antibody lines may confirm or support a diagnosis of liver disease, guide treatment decisions, or help monitor disease activity. Negative results can rule out specific autoimmune or infectious causes of liver dysfunction, but further testing may still be needed.

Short name

Liver Disease Antibody Profile

Frequently asked questions

What does a positive result mean?
A positive result indicates the presence of antibodies linked to liver disease, which may suggest an autoimmune process, chronic infection, or metabolic disorder. This doesn’t always mean you have an active disease, so follow-up testing and discussion with your doctor are important.
Can this test replace other liver function tests?
No, this test is one tool among many. It’s often used alongside liver enzymes (like ALT/AST), imaging, and clinical symptoms to provide a full picture. Your doctor will interpret results in the context of your overall health.
How long does it take to get results?
Results are typically available within 2–5 business days, depending on lab processing times. Your doctor will contact you once they’re ready, but they may also discuss preliminary findings during your visit.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy